Cargando…

Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia

Detalles Bibliográficos
Autores principales:	Peng, Yanren, Guo, Danxia, Jiang, Sijie, Zheng, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276344/ https://www.ncbi.nlm.nih.gov/pubmed/34924503 http://dx.doi.org/10.1097/CM9.0000000000001896

Ejemplares similares

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
por: Choi, Joshua, et al.
Publicado: (2017)

Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver
por: Shafiq, Muhammad, et al.
Publicado: (2020)

Identification of Novel Proteins Interacting with Proprotein Convertase Subtilisin/Kexin 9
por: Melendez, Quantil M., et al.
Publicado: (2020)

Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review
por: Wu, Na-Qiong, et al.
Publicado: (2022)

Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden
por: Landmesser, Ulf, et al.
Publicado: (2020)

The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease
por: Kim, Eun Ji, et al.
Publicado: (2020)

Proprotein Convertase Subtilisin/Kexin 6 in Cardiovascular Biology and Disease
por: Wu, Qingyu, et al.
Publicado: (2022)

Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9
por: Chen, I-Chih, et al.
Publicado: (2017)

Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies
por: Ferri, Nicola, et al.
Publicado: (2020)

Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis
por: Poznyak, Anastasia V., et al.
Publicado: (2023)

Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
por: Schulz, Rainer, et al.
Publicado: (2015)

Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9
por: Jang, Hyun-Duk, et al.
Publicado: (2020)

Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease
por: Suur, Bianca E., et al.
Publicado: (2022)

Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR
por: Wang, Yan, et al.
Publicado: (2012)

Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9
por: Gu, Hong-mei, et al.
Publicado: (2015)

Variations of the proprotein convertase subtilisin/kexin type 9 gene in coronary artery disease
por: Chiang, Shih-Min, et al.
Publicado: (2019)

Corrigendum to: Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies
Publicado: (2021)

Lipid Parameters and Proprotein Convertase Subtilisin/Kexin Type 9 in Healthy Lebanese Adults
por: Gannagé-Yared, Marie-Hélène, et al.
Publicado: (2022)

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
por: O’Connell, Emma M., et al.
Publicado: (2020)

Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects
por: Duprez, Daniel A, et al.
Publicado: (2020)

Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
por: Pickett, June K., et al.
Publicado: (2020)

Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
por: Gibbs, John P., et al.
Publicado: (2016)

Proprotein convertase subtilisin/kexin type 9: A new target molecule for gene therapy
por: Banaszewska, Anna, et al.
Publicado: (2012)

Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves’ Orbitopathy in Orbital Fibroblasts
por: Lee, Ga Eun, et al.
Publicado: (2021)

Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9
por: Schlüter, Klaus-Dieter, et al.
Publicado: (2020)

Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis
por: Lawler, Patrick R., et al.
Publicado: (2023)

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control
por: Rikhi, Rishi, et al.
Publicado: (2023)

Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
por: Athavale, Dipti, et al.
Publicado: (2018)

Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome
por: Metkus, Thomas S., et al.
Publicado: (2022)

Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia
por: Mazhar, Faizan, et al.
Publicado: (2016)

Statin-associated muscle symptoms: is Proprotein convertase subtilisin/kexin type 9 inhibitors a therapeutic option?
por: Corsini, Alberto
Publicado: (2019)

Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use: a narrative review
por: Yuet, Wei C., et al.
Publicado: (2021)

Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways
por: Cammisotto, Vittoria, et al.
Publicado: (2021)

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Use for Atherogenic Dyslipidemia in Solid Organ Transplant Patients
por: Cuomo, Gianluigi, et al.
Publicado: (2022)

Acute coronary syndromes: hospital management of dyslipidaemia with proprotein convertase subtilisin/kexin 9 inhibitors: time to act
por: Musumeci, Giuseppe, et al.
Publicado: (2023)

Proprotein convertase subtilisin/Kexin type-9 (PCSK-9) inhibitors induced liver injury - a retrospective analysis
por: Zafar, Yousuf, et al.
Publicado: (2020)

The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia
por: Parikh, Riya R, et al.
Publicado: (2022)

Plasma Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) as a Possible Biomarker for Severe COVID-19
por: Mester, Patricia, et al.
Publicado: (2023)

Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases
por: Ferri, Nicola
Publicado: (2012)

Efficacy and safety of proprotein convertase subtilisin/kexin type 9 monoclonal antibody in adults with familial hypercholesterolemia
por: Li, Bin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7k13cj9h5ruun71ps0snqsdhkp